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Abstract
Background: Cyclo-oxygenase-2 (COX-2), the key enzyme in the conversion of arachidonic acid
to prostaglandins, is involved in critical steps of tumor onset and progression, and is a strong
predictor of chemotherapy resistance and poor outcome in advanced ovarian cancer. To our
knowledge, no data has been reported until now about the association between COX-2 status and
response to different chemotherapy regimens.
Methods: A retrospective study was performed to investigate the association of COX-2 with
outcome and response to platinum versus platinum/paclitaxel in 68 primary ovarian cancer. COX-
2 immunoreaction was performed on paraffin-embedded sections by using rabbit polyclonal
antiserum against COX-2.
Results: In the overall series, COX-2 positivity was found in a statistically significant higher
percentage of not responding cases than in patients responding to chemotherapy (n = 15/21; 71.4%
versus n = 17/47; 36.1%; p value = 0.0072). A higher percentage of COX-2 positivity was found in
patients unresponsive (n = 11/13; 84.6%) versus patients responsive to platinum-based
chemotherapy (n = 9/26; 34.6%). In cases administered platinum/paclitaxel, COX-2 positivity was
found in 4 out of 8 (50%) of un responsive versus 8 out of 21 (38.1%) of responsive cases. Logistic
regression analysis of parameters likely to affect response to treatment resulted in a p value = 0.17
for the interaction COX-2/type of treatment.
Conclusion: Although these findings need to be confirmed in a larger series, our study suggests a
possible indication that there is a difference in the influence of COX-2 on response depending on
treatment regimen.
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Background
Ovarian cancer represents the fifth leading cause of death
for cancer in women [1]. More than 70% of cases present
with advanced stage of disease at diagnosis and despite
advances in cytoreductive surgery and establishment of
carboplatin/paclitaxel combination as the standard chem-
otherapy regimen, intrinsic or acquired tumor chemore-
sistance remains the major determinant of chemotherapy
failure and unfavourable clinical outcome [1,2].
Several molecular alterations have been proposed to sup-
port tumor resistance to cytotoxic drugs, such as the
expression of MDR phenotype, mutation of p53, bcl2
overexpression [3-5], but only very recently it has been
recognized that specific molecular or biological profiles
might characterize tumor sensitivity to classes of agents
with different mechanisms of action. For instance, muta-
tion of p53 has been demonstrated to be strictly associ-
ated with platinum resistance in in vitro, and preclinical
models as well as in humans [4,6], while it is likely to sus-
tain a higher chance of susceptibility to paclitaxel contain-
ing regimens [7,8]. Recently, expression of survivin, a
member of the inhibitors of apoptosis protein [9], has
been shown to be unrelated to response to cisplatin-based
treatment, while its overexpression correlates with resist-
ance to paclitaxel/platinum containing regimen in
advanced ovarian carcinoma [10].
We showed that cyclooxygenase-2 (COX-2), the key
enzyme in the conversion of arachidonic acid to prostag-
landins, involved in critical steps of tumor onset and pro-
gression [10], is a strong predictor of chemotherapy
resistance and poor outcome in advanced ovarian cancer,
as well as cervical cancer patients [12-14]. These findings,
also confirmed in other solid tumors, have also provided
the rationale for the combination of selective COX-2
inhibitors with cytotoxic agents [15,16].
To our knowledge, no data has been reported until now
about the association between COX-2 status and response
to different chemotherapy regimens.
The aim of the study was to investigate the association of
COX-2 with outcome and response to platinum versus
platinum/paclitaxel containing regimens as first line treat-
ment in a single institutional series of primary untreated
advanced ovarian cancer patients.
Methods
Patient data
A retrospective analysis of 68 ovarian cancer patients
admitted to the Gynecologic Oncology Unit, Catholic
University of Rome was planned. The study was approved
by our Ethical Committee. Staging was performed accord-
ing to FIGO classification. In order to make the analysis of
the association with response to chemotherapy and out-
come the most reliable, a very homogenous series of stage
IIIC-IV ovarian cancer patients with measurable disease
after primary surgery were included in the study.
Within 2–3 weeks after surgery, all patients underwent 4
to 6 cycles of cisplatin-based (75–100 mg/m2 for each
cycle) or platinum/paclitaxel containing (175 mg/m2 for
each cycle) chemotherapy. Response to chemotherapy
was specifically assessed by gynecological examination,
total body CT scan, analysis of CA125 levels. Response to
treatment was recorded according to WHO criteria [17], as
follows: complete response was defined as disappearance
of all clinically detectable disease lesions for at least 4
weeks; partial response was defined as more than 50%
reduction in the sum of the products of the two largest
perpendicular diameters of bidimensionally measurable
lesions for at least 4 weeks; stable disease was defined as
regression not meeting the aforementioned criteria for
objective response; all other cases were considered to have
progressive disease.
For the analysis of the association between COX-2 status
and response to treatment patients were categorized in
responsive (clinical complete and partial response) versus
not responsive cases (no change/progression)
Immunohistochemistry
COX-2 immunoreaction was performed as previously
described [12,13]. Briefly, four µm sections of representa-
tive formalin-fixed paraffin-embedded blocks from each
case were deparaffinized in xylene, rehydrated, treated
with 0.3% H2O2 in methanol for 10 min, and subjected to
heat-induced epitope retrieval in microwave oven using
the Dako ChemMate detection kit (DAKO, Glostrup,
Denmark). Slides were then simultaneously processed for
immunohistochemistry on the TechMate Horizon auto-
mated staining system (DAKO) using the Vectastain ABC
peroxidase kit (Vector Laboratories, Burlingame, CA). Sec-
tions were incubated with normal rabbit serum for 15
min, then with rabbit polyclonal antiserum against COX-
2 (Cayman, Ann Arbor, MI, USA) diluted 1:300, for 1 h.
Negative controls were performed using non immunized
rabbit serum or by omitting the primary antiserum.
The laboratory analysis of COX-2 and evaluation of
immunohistochemical results were done without any
prior knowledge of the clinical parameters by two differ-
ent pathologists (FOR, GFZ) by means of light micros-
copy. Proportion of immunostained cells was scored at
low magnification (5 × objective lens) by evaluating the
entire tumor area. In case of disagreement (n = 6/68,
8.8%), the sections were submitted to a rejoint evalua-
tion. When tumor area with positive immunostaining wasBMC Cancer 2006, 6:182 http://www.biomedcentral.com/1471-2407/6/182
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in excess of 10 % of total tumor area, the case was scored
as positive.
Statistical analysis
Fisher's exact test or χ2 test were used to analyze the distri-
bution of COX-2 positive cases according to clinico-path-
ological features and response to treatment.
Progression free survival (PFS) was calculated from the
date of diagnosis to the date of progression or date last
seen. Medians and life tables were computed using the
product-limit estimate by the Kaplan and Meier method
[18] and the log-rank test was employed to assess the sta-
tistical significance [19]. Stepwise logistic regression was
used to analyze the role of clinico-pathological parame-
ters as predictors of response to treatment and included
the interaction COX-2/type of treatment.
Statistical analysis was carried out using SOLO (BMDP
Statistical Software, Los Angeles, CA).
Results
Table 1 summarizes the clinico-pathological characteris-
tics of cases in the whole series and according to the type
of first line chemotherapy agents.
In the overall series median age was 57 years (range: 28–
81). Fifty cases (73.5%) were stage IIIC and 18 (26.5%)
were stage IV disease.
Cytoreduction to residual tumor 0.5–1 cm was achieved
in 18 (26.5%) of cases, while cytoreduction to residual
tumor >1 cm was accomplished in 23 (33.8%) of cases. In
27 (39.7%) cases only multiple biopsies (exploratory
laparotomy) were performed.
Table 1: Clinico-pathological characteristics of the patients in the whole series, and according to type of chemotherapy
Characteristics No. of patients Platinum-containing 
chemotherapy No. (%)
Platinum/paclitaxel containing 
chemotherapy No. (%)
All cases 68 39 29
Age (yrs)
<60 43 22 (51.2) 21 (48.8)
≥60 25 17 (68.0) 8 (32.0)
FIGO Stage
IIIC 50 31 (62.0) 19 (38.0)
IV 18 8 (44.4) 10 (55.6)
Cytoreduction
RT <1 cm 18 12 (66.7) 6 (33.3)
RT ≥1 cm 50 27 (54.0) 7 (14.0)
Ascites
No 16 8 (50.0) 8 (50.0)
Yes 52 29 (55.8) 23 (44.2)
Histotype
Serous 54 32 (59.2) 22 (40.7)
Endometrioid 8 5 (62.5) 3 (37.5)
Undifferentiated 6 2 (33.3) 4 (66.7)
Other 3 2 (66.7) 1 (33.3)
Grade
G1-2 10 8 (80.0) 2 (20.0)
G3 53 30 (56.6) 23 (43.4)
n.a. 5
COX-2
Negative 36 19 (52.8) 17 (47.2)
Positive 32 20 (62.5) 12 (37.5)
Table 2: Distribution of COX-2 positive cases according to response to chemotherapy
Overall series P value
Response to chemotherapy No. COX-2 positive No.(%)
Responsive 47 17 (36.1)
Not responsive 21 15 (71.4) 0.0072
*calculated by Fisher's exact testBMC Cancer 2006, 6:182 http://www.biomedcentral.com/1471-2407/6/182
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Overall, COX-2 positivity was documented in 32/68 cases
(47.0%). In COX-2 positive cases the percentage of posi-
tive staining per total tumor area ranged from 15% to
45% (median value 20%). Although the use of raw data
provides more information, we decided to use the cut-off
value in order to define different risk patient categories.
There was no difference in the distribution of age, stage,
residual tumor, and histopathological findings, in cases
administered platinum versus platinum/paclitaxel con-
taining chemotherapy. As far as response to chemother-
apy is concerned, in the overall series 47 patients (69.1%)
were considered to be responsive to treatment, while 21
(30.9%) patients were classified as no responders (Table
2).
In Table 2 the association between COX-2 status and
response to chemotherapy in the overall series is also
summarized: COX-2 positivity was found in a statistically
significant higher percentage of not responding cases than
in patients responding to chemotherapy (n = 15/21;
71.4% versus n = 17/47; 36.1%; p value = 0.0072).
Logistic regression analysis including variables likely to
affect response to treatment showed that the extent of
residual tumor at surgery maintained an independent role
as predictor of resistance to treatment (Table 3). The p
value of 0.17 of the interaction COX-2/type of treatment
suggests that the role of COX-2 on differential response
depending on different treatments needs to be clarified in
a larger series of cases.
As shown in Table 4, in the group of patients administered
platinum-based chemotherapy, COX-2 positivity was
found in 11 out of 13 (84.6%) of not responding patients
versus 9 out of 26 (34.6%) of responding patients. On the
other hand, in cases administered platinum/paclitaxel
containing chemotherapy, COX-2 positivity was found in
4 out o 8 (50.0%) of unresponsive versus 8 out of 21
(38.1%) of responsive cases.
Survival analysis
Follow up data were available for 68 patients. The median
follow up was 33 months (range 4–214). During the fol-
low up period, progression of disease was observed in 59
(86.8%) cases. Figure 1 shows the progression free sur-
vival (PFS) curve in our population according to type of
cytotoxic drugs in the first line treatment. There was no
statistically significant difference of clinical outcome in
patients administered platinum-based versus platinum/
paclitaxel containing chemotherapy (p value = 0.44),
Discussion
This is the first study investigating the association between
COX2 status and susceptibility to chemotherapy accord-
ing to type of cytotoxic agents used in first line treatment
Table 3: Logistic regression analysis of clinico-pathological parameters, and COX-2 status as predictors of response to treatment in 
ovarian cancer patients
Variable* χ2 estimate p value
Stage 0.11 0.7
Residual tumor 4.52 0.03
COX-2 status 2.04 0.09
Type of chemotherapy 2.10 0.11
Interaction 1.7 0.17
Response was subgrouped as follows: complete/partial vs no change of disease/progression.
*Variables were subgrouped as follows: stage III vs IV; residual tumor <2 cm vs ≥2 cm; negative vs positive COX-2 status; interaction COX-2 status/
type of treatment
Table 4: COX-2 positive cases according to response to chemotherapy in the two treatment groups
Platinum-containing 
chemotherapy
P value* Platinum/paclitaxel containing 
chemotherapy
P value*
Response to CT No. COX-2 positive 
No. (%)
No. COX-2 positive 
No. (%)
Responsive 26 9 (34.6) 21 8 (38.1)
Not responsive 13 11 (84.6) 0.0057 8 4 (50.0) 0.43
*calculated by Fisher's exact testBMC Cancer 2006, 6:182 http://www.biomedcentral.com/1471-2407/6/182
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of advanced ovarian cancer with measurable disease after
first surgery.
Our findings suggest that there could be a difference in the
influence of COX-2 expression depending on type of
chemotherapeutic regimen (a difference greater in plati-
num-based treated cases), although a larger sample series
is needed before a definitive conclusion can be drawn.
Our data seems to confirm the association between high
COX-expression and poor chance of response to chemo-
therapy reported in ovarian and cervical tumors
[13,14,20]. This finding remains to be clarified at bio-
chemical level, although it is conceivable that the involve-
ment of COX-2 in the crucial biochemical pathways of
tumor cell biology might play a major role: indeed, COX-
2 has been reported to induce the antiapoptotic bcl-2 pro-
tein [21], and to be associated with neoangiogenesis in
tumor bearing mice [22]. Since both inhibition of apop-
tosis and promotion of neoangiogenesis are strictly asso-
ciated with chemotherapy resistance, it is conceivable that
COX-2 expression could play a role as indicator of plati-
num resistance in ovarian cancer. Moreover, biochemical
links between COX-2 and peptidic growth factor system
alterations, which are renowned to be associated with
resistance to several cytotoxic agents, have been docu-
mented [23,24]. Finally, very recent evidences demon-
strated the relevant role of COX-2 in the inhibition of
DNA damage induction of apoptosis mediated by p53
[25,26]; therefore, tumors overexpressing COX2 are likely
to exhibit a reduction of wild-type p53 mediated apopto-
sis induced by DNA damaging chemotherapeutics, such as
platinum compounds, alkylants and anthracyclines, often
used in combination. Indeed, a direct association between
high COX-2 content and overexpression/mutation of p53
has been reported in ovarian tumors, although conflicting
data has been also provided [27-29].
Although the relatively small sample series has to be taken
into account as a limit to the power of the analysis, it is
conceivable that the addition of taxanes could hinder the
COX-2 involvement in drug resistance, by acting on differ-
ent molecular targets such as microtubule function or bcl-
2 [30,31].
It remains to be clarified why there was no significant dif-
ference in terms of response rate and clinical outcome in
patients administered platinum versus platinum/paclit-
axel containing regimens: even if the impact of the rela-
tively small size of our sample series cannot be ruled out,
an alternative intriguing working hypothesis is repre-
sented by the interference of taxanes with COX-2 pro-
moted pathways. Indeed, it has been reported that the two
clinically available taxanes, namely paclitaxel and
docetaxel increase COX-2 expression by inducing mRNA
transcription and stabilization [32-35]. Moreover, the
addition of the specific COX-2 inhibitor celecoxib has
been shown to abrogate the marked increase of PGE2 lev-
els observed in non small cell lung cancer patients after
carboplatin/paclitaxel administration [36]. Whether the
potentiation of COX-2 promoted activities by taxanes
could influence the overall sensitivity of ovarian cancer
cells to the combination platinum/paclitaxel, by conceiv-
ably reducing the favourable impact of paclitaxel addi-
tion, remains to be verified. In this context, it is
noteworthy that the vast majority of the studies exploring
the association of taxanes with COX-2 inhibitors were
able to document a synergistic antitumor activity in vitro
and in vivo [33-35].
Finally, although the significance of our findings is not
certain given that the standard first-line treatment for
ovarian cancer is a combination of platinum with a tax-
ane, we think that our data could provide, if confirmed in
a wider series, the rationale to ask for the immunohisto-
chemical assessment of COX-2 status as predictor of
response to treatment, only in cases triaged to platinum-
based therapy (including platinum/anthracycline or plat-
inum/alkylants combinations, which are still a valid
option in selected patients).
Conclusion
Although these findings need to be confirmed in a larger
series, our study suggests a possible indication that there
is a difference in the influence of COX-2 on response
depending on treatment regimen. The analysis of COX-2
expression in ovarian cancer tissues before and after car-
boplatin/paclitaxel treatment in patients submitted to
exploratory laparotomy and interval debulking surgery
after successful neoadjuvant treatment, would be helpful
Progression free survival (PFS) curve in ovarian cancer  patients administered platinum containing versus platinum/ paclitaxel containing regimen Figure 1
Progression free survival (PFS) curve in ovarian cancer 
patients administered platinum containing versus platinum/
paclitaxel containing regimen.BMC Cancer 2006, 6:182 http://www.biomedcentral.com/1471-2407/6/182
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in order to assess whether this regimen can modulate
COX-2 expression in vivo, as very recently reported by
Altorki et al. [37].
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